Common serotonergic drugs |
|
Class |
Drugs |
SSRIs |
citalopram, escitalopram, fluoxetine, paroxetine, sertraline |
Serotonin and Noradrenaline Reuptake Inhibitor (SNRIs) |
venlafaxine |
Monoamine Oxidase Inhibitors (MAOIs) |
moclobemide, tranylcypromine, phenelzine |
tricyclic antidepressants (TCAs) |
amitriptyline, clomipramine, nortriptyline |
Noradrenergic and Specific Serotonergic Antidepressant (NaSSa) |
mirtazapine |
analgesics |
pethidine, tramadol |
triptans |
sumatriptan |
other |
buspirone, carbamazepine, lithium, valproate sodium |
herbal medicines |
St John’s wort |
Drugs with strong, moderate, or weak anticholinergic potency |
|||
|
Strong |
Moderate |
Weak |
Antidepressants: |
amitriptyline, clomipramine, paroxetine |
nortriptyline and all other ‘non-strong’ tricyclic antidepressants |
mirtazapine, venlafaxine |
Antihistamines: |
promethazine |
|
cetirizine, loratadine, ranitidine |
Antipsychotics: |
chlorpromazine, clozapine |
olanzapine, quetiapine |
aripiprazole, haloperidol, lithium, risperidone |
Anticholinergics: |
benzatropine, oxybutynin, solifenacin, tolterodine (may be selective for bladder acetylcholine receptors) |
hyoscine, procyclidine |
|
Antiparkinsonian: |
|
amantadine |
carbidopa-levodopa, entacapone, pramipexole, ropinirole, selegiline |
Antiemetic: |
prochlorperazine |
|
metoclopramide |
Others: |
|
baclofen, carbamazepine, loperamide (usually local effect on the gut only) |
codeine, digoxin, tramadol, warfarin |
NB *Inhaled e.g. tiotropium, ipratropium, glycopyrronium, umeclidinium or topical anticholinergic drugs have low systemic exposure but may have systemic effects at high doses or in susceptible patients.
QTc prolonging drugs |
||||
Class |
Drugs |
|||
antiarrhythmics |
amiodarone |
flecainide |
sotalol |
|
CNS drugs |
antipsychotics |
SSRIs |
tricyclic antidepressants |
lithium |
macrolide antimicrobials |
azithromycin |
clarithromycin |
erythromycin |
roxithromycin |
other |
cisapride |
chloroquine |
domperidone |
methadone |
ECG measurement of the QTc interval prior to and early on in treatment (when at, or approaching, steady-state) is recommended for all patients:
Topic Code: 93252